Alicia G Lydecker1, Abhisheak Sharma2, Christopher R McCurdy3, Bonnie A Avery2,3, Kavita M Babu4, Edward W Boyer4. 1. Division of Medical Toxicology, Department of Emergency Medicine, University of Massachusetts Medical School, 55 Lake Ave North, Worcester, MA, 01655, USA. alicia.lydecker@gmail.com. 2. Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, 104A Faser Hall, P.O. Box 1848, University, MS, 38677-1848, USA. 3. Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, 417 Faser Hall, P.O. Box 1848, University, MS, 38677-1848, USA. 4. Division of Medical Toxicology, Department of Emergency Medicine, University of Massachusetts Medical School, 55 Lake Ave North, Worcester, MA, 01655, USA.
Abstract
INTRODUCTION: Kratom (Mitragyna speciosa), a plant native to Southeast Asia, has been used for centuries for its stimulant and opium-like effects. Mitragynine and 7-hydroxymitragynine, exclusive to M. speciosa, are the alkaloids primary responsible for Kratom's biologic and psychoactive profile, and likely contribute to its problematic use. We purchased several commercially available Kratom analogs for analysis and through our results, present evidence of probable adulteration with the highly potent and addictive plant alkaloid, 7-hydroxymitragynine. METHODS: A simple and sensitive LC-MS/MS method was developed for simultaneous quantification of mitragynine and 7-hydroxymitragynine in methanol extract of marketed Kratom supplements. RESULTS: We found multiple commercial Kratom products to have concentrations of 7-hydroxymitragynine that are substantially higher than those found in raw M. speciosa leaves. CONCLUSIONS: We have found multiple packaged commercial Kratom products likely to contain artificially elevated concentrations of 7-hydroxymitragynine, the alkaloid responsible for M. speciosa's concerning mechanistic and side effect profile. This study describes a unique form of product adulteration, which stresses the importance of increased dietary supplement oversight of Kratom-containing supplements.
INTRODUCTION: Kratom (Mitragyna speciosa), a plant native to Southeast Asia, has been used for centuries for its stimulant and opium-like effects. Mitragynine and 7-hydroxymitragynine, exclusive to M. speciosa, are the alkaloids primary responsible for Kratom's biologic and psychoactive profile, and likely contribute to its problematic use. We purchased several commercially available Kratom analogs for analysis and through our results, present evidence of probable adulteration with the highly potent and addictive plant alkaloid, 7-hydroxymitragynine. METHODS: A simple and sensitive LC-MS/MS method was developed for simultaneous quantification of mitragynine and 7-hydroxymitragynine in methanol extract of marketed Kratom supplements. RESULTS: We found multiple commercial Kratom products to have concentrations of 7-hydroxymitragynine that are substantially higher than those found in raw M. speciosa leaves. CONCLUSIONS: We have found multiple packaged commercial Kratom products likely to contain artificially elevated concentrations of 7-hydroxymitragynine, the alkaloid responsible for M. speciosa's concerning mechanistic and side effect profile. This study describes a unique form of product adulteration, which stresses the importance of increased dietary supplement oversight of Kratom-containing supplements.
Entities:
Keywords:
7-Hydroxymitragynine; Drugs of abuse; Kratom; Mitragyna speciosa; Mitragynine
Authors: Eung-Sun Lee; Ji Won Kim; Ji Hyun Lee; Kyoung Moon Han; Sooyeul Cho; Insun Hwang; Soon Young Han; Kabyong Chae; Jinho Kim Journal: Food Addit Contam Part A Chem Anal Control Expo Risk Assess Date: 2013-02-18
Authors: Caroline Mathon; Anita Ankli; Eike Reich; Stefan Bieri; Philippe Christen Journal: Food Addit Contam Part A Chem Anal Control Expo Risk Assess Date: 2014-01-15
Authors: Shyam H Kamble; Abhisheak Sharma; Tamara I King; Erin C Berthold; Francisco León; P Katharina L Meyer; Siva Rama Raju Kanumuri; Lance R McMahon; Christopher R McCurdy; Bonnie A Avery Journal: Toxicol Lett Date: 2019-11-07 Impact factor: 4.372
Authors: Erin C Berthold; Shyam H Kamble; Kanumuri S Raju; Michelle A Kuntz; Alexandria S Senetra; Marco Mottinelli; Francisco León; Luis F Restrepo; Avi Patel; Nicholas P Ho; Takato Hiranita; Abhisheak Sharma; Lance R McMahon; Christopher R McCurdy Journal: Drug Metab Dispos Date: 2021-11-10 Impact factor: 3.922
Authors: Elizabeth A Maxwell; Tamara I King; Shyam H Kamble; Kanumuri Siva Rama Raju; Erin C Berthold; Francisco León; Aidan Hampson; Lance R McMahon; Christopher R McCurdy; Abhisheak Sharma Journal: Eur J Drug Metab Pharmacokinet Date: 2021-04-13 Impact factor: 2.441
Authors: Shyam H Kamble; Erin C Berthold; Tamara I King; Siva Rama Raju Kanumuri; Raluca Popa; Julius R Herting; Francisco León; Abhisheak Sharma; Lance R McMahon; Bonnie A Avery; Christopher R McCurdy Journal: J Nat Prod Date: 2021-02-23 Impact factor: 4.050
Authors: Rhiannon Bath; Tanner Bucholz; Amy F Buros; Darshan Singh; Kirsten E Smith; Charles A Veltri; Oliver Grundmann Journal: J Addict Med Date: 2020 May/Jun Impact factor: 4.647
Authors: Mengzi Zhang; Abhisheak Sharma; Francisco León; Bonnie Avery; Roger Kjelgren; Christopher R McCurdy; Brian J Pearson Journal: PLoS One Date: 2022-04-26 Impact factor: 3.752